fda warning letters compounded glp-1 september 2025 Why the Issued 30 to Telehealth Sites Marketing GLP-1s US FDA sends 25 letters
Description
Impermissible Advertising: LegitScript has found that 83% of problematic ads for GLP-1 medications are being promoted in jurisdictions where advertisements for prescription medicines are not allowed

doi: 10.4093/dmj.2020.0258

But it wont make it available to everyone
It is a great product that I will order again Everything has been smooth sailing since starting with VItastir, I could not be more pleased, I can only hope pray that the quality and dedication they have shown continues

Intermediate values were observed for liraglutide (11 days, IQR 257), tirzepatide (19 days, IQR 369), lixisenatide (20 days, IQR 5116), and semaglutide (27 days, IQR 577) (Table S6)
